Mice with reduced vesicular monoamine storage content display nonmotor features of Parkinson's disease

Journal of Neuroscience

Volumn 29, Issue 41, 2009, Pages 12842-12844

  Vernon, Anthony C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; BRAIN MONOAMINE; DOPAMINE; LEVODOPA; NEUROTRANSMITTER; NORADRENALIN; OXIDOPAMINE; ROTENONE; SEROTONIN; VESICULAR MONOAMINE TRANSPORTER 2; BIOGENIC AMINE; NEUROTOXIN; VESICULAR MONOAMINE TRANSPORTER;

ANXIETY; AUTONOMIC DYSFUNCTION; CELL VACUOLE; COGNITIVE DEFECT; CONSTIPATION; DEMENTIA; DEPRESSION; DIGESTIVE SYSTEM FUNCTION DISORDER; GASTROINTESTINAL TRACT FUNCTION; HUMAN; LOCUS CERULEUS; NERVE DEGENERATION; NONHUMAN; NORADRENERGIC SYSTEM; NOTE; OLFACTORY DISCRIMINATION; PAIN; PARASOMNIA; PARKINSON DISEASE; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; SEROTONINERGIC SYSTEM; SLEEP; SLEEP DISORDER; SMELLING DISORDER; ANIMAL; DISEASE MODEL; GENETICS; METABOLISM; MOUSE; PATHOPHYSIOLOGY;

ANIMALS; BIOGENIC MONOAMINES; DISEASE MODELS, ANIMAL; MICE; NEUROTOXINS; PARKINSON DISEASE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 70350461640     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.4156-09.2009     Document Type: Note

References (28)

1. Aarsland D, Brønnick K, Alves G, Tysnes OB, Pedersen KF, Ehrt U, Larsen JP (2009) The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. J Neurol Neurosurg Psychiatry 80:928-930.
2. Anderson G, Noorian AR, Taylor G, Anitha M, Bernhard D, Srinivasan S, Greene JG (2007) Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease. Exp Neurol 207:4-12. (Pubitemid 47332479)
3. Barraud Q, Lambrecq V, Forni C, McGuire S, Hill M, Bioulac B, Balzamo E, Bezard E, Tison F, Ghorayeb I (2009) Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model. Exp Neurol 219:574-582.
4. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211. (Pubitemid 36007810)
5. Branchi I, D'Andrea I, Armida M, Cassano T, Pèzzola A, Potenza RL, Morgese MG, Popoli P, Alleva E (2008) Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model. J Neurosci Res 86:2050-2061.
6. Brooks DJ (2007) Imaging non-dopaminergic function in Parkinson's disease. Mol Imaging Biol 9:217-222. (Pubitemid 47028737)
7. Caudle WM, Richardson JR, Wang MZ, Taylor TN, Guillot TS, McCormack AL, Colebrooke RE, Di Monte DA, Emson PC, Miller GW (2007) Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci 27:8138-8148.
8. Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8:464-474.
9. Chudler EH, Lu Y (2008) Nociceptive behavioral responses to chemical, thermal and mechanical stimulation after unilateral, intrastriatal administration of 6-hydroxydopamine. Brain Res 1213:41-47.
10. Drolet RE, Cannon JR, Montero L, Greenamyre JT (2009) Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology. Neurobiol Dis 36:96-102.
11. Ferro MM, Bellissimo MI, Anselmo-Franci JA, Angellucci ME, Canteras NS, Da Cunha C (2005) Comparison of bilaterally 6-OHDA-and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. J Neurosci Methods 148:78-87.
12. Fleming SM, Tetreault NA, Mulligan CK, Hutson CB, Masliah E, Chesselet MF (2008) Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. Eur J Neurosci 28: 247-256.
13. George S, van den Buuse M, SanMok S, Masters CL, Li QX, Culvenor JG (2008) Alpha-synuclein transgenic mice exhibit reduced anxiety-like behaviour. Exp Neurol 210:788-792.
14. Greene JG, Noorian AR, Srinivasan S (2009) Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease. Exp Neurol 218:154-161.
15. Jenner P (2008) Functional models of Parkinson's disease: a valuable tool in the development of novel therapies. Ann Neurol 64 [Suppl 2]:S16-S29.
16. Langston JW (2006) The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 59:591-596.
17. Marek K, Jennings D (2009) Canweimagepremotor Parkinson disease? Neurology 72:S21-26.
18. Monaca C, Laloux C, Jacquesson JM, Gelé P, Maréchal X, Bordet R, Destée A, Derambure P (2004) Vigilance states in a parkinsonian model, the MPTP mouse. Eur J Neurosci 20:2474-2478. (Pubitemid 39472409)
19. Mooslehner KA, Chan PM, Xu W, Liu L, Smadja C, Humby T, Allen ND, Wilkinson LS, Emson PC (2001) Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for parkinsonism. Mol Cell Biol 21:5321-5331. (Pubitemid 32702438)
20. Prediger RD, Aguiar AS Jr, Rojas-Mayorquin AE, Figueiredo CP, Matheus FC, Ginestet L, Chevarin C, Bel ED, Mongeau R, Hamon M, Lanfumey L, Raisman-Vozari R (2009) Single intranasal administration of 1-methyl-4- phenyl-1,2,3,6- tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease. Neurotox Res. Advance online publication. Retrieved July 21, 2009. doi:10.1007/s12640-009-9087-0.
21. Reksidler AB, Lima MM, Zanata SM, Machado HB, da Cunha C, Andreatini R, Tufik S, Vital MA (2007) The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. Eur J Pharmacol 560:163-175. (Pubitemid 46341312)
22. Rosland JH, Hunskaar S, Broch OJ, Hole K (1992) Acute and long term effects of 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP) in tests of nociception in mice. Pharmacol Toxicol 70:31-37.
23. Tadaiesky MT, Dombrowski PA, Figueiredo CP, Cargnin-Ferreira E, Da Cunha C, Takahashi RN (2008) Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 156:830-840.
24. Tassorelli C, Armentero MT, Greco R, Fancellu R, Sandrini G, Nappi G, Blandini F (2007) Behavioral responses and Fos activation following painful stimuli in a rodent model of Parkinson's disease. Brain Res 1176:53-61. (Pubitemid 47553126)
25. Taylor TN, Caudle WM, Shepherd KR, Noorian A, Jackson CR, Iuvone PM, Weinshenker D, Greene JG, Miller GW (2009) Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J Neurosci 29:8103-8113.
26. Vucković MG, Wood RI, Holschneider DP, Abernathy A, Togasaki DM, Smith A, Petzinger GM, Jakowec MW (2008) Memory, mood, dopamine, and serotonin in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. Neurobiol Dis 32:319-327.
27. Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA (2007) Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 130:1787-1798. (Pubitemid 47343805)
28. Zhu XR, Maskri L, Herold C, Bader V, Stichel CC, Güntürkün O, Lübbert H (2007) Non-motor behavioural impairments in parkin-deficient mice. Eur J Neurosci 26:1902-1911. (Pubitemid 47493196)